Artiva Biotherapeutics (ARTV) Competitors $2.55 -0.11 (-4.14%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.57 +0.02 (+0.78%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARTV vs. ACB, LRMR, OCGN, GLUE, DMAC, SCPH, CTNM, FDMT, CAPR, and FHTXShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Aurora Cannabis (ACB), Larimar Therapeutics (LRMR), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), DiaMedica Therapeutics (DMAC), scPharmaceuticals (SCPH), Contineum Therapeutics (CTNM), 4D Molecular Therapeutics (FDMT), Capricor Therapeutics (CAPR), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Artiva Biotherapeutics vs. Its Competitors Aurora Cannabis Larimar Therapeutics Ocugen Monte Rosa Therapeutics DiaMedica Therapeutics scPharmaceuticals Contineum Therapeutics 4D Molecular Therapeutics Capricor Therapeutics Foghorn Therapeutics Aurora Cannabis (NASDAQ:ACB) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation. Does the media prefer ACB or ARTV? In the previous week, Aurora Cannabis had 3 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Aurora Cannabis and 1 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 1.91 beat Aurora Cannabis' score of 0.73 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aurora Cannabis Positive Artiva Biotherapeutics Very Positive Do analysts prefer ACB or ARTV? Artiva Biotherapeutics has a consensus target price of $17.00, indicating a potential upside of 566.67%. Given Artiva Biotherapeutics' higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in ACB or ARTV? 47.6% of Aurora Cannabis shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by company insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, ACB or ARTV? Aurora Cannabis has higher revenue and earnings than Artiva Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$357.88M0.77$1.63M-$0.19-25.63Artiva BiotherapeuticsN/AN/A-$65.37MN/AN/A Which has more volatility & risk, ACB or ARTV? Aurora Cannabis has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Artiva Biotherapeutics has a beta of 2.99, indicating that its share price is 199% more volatile than the S&P 500. Is ACB or ARTV more profitable? Artiva Biotherapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -5.66%. Aurora Cannabis' return on equity of -1.49% beat Artiva Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis-5.66% -1.49% -1.06% Artiva Biotherapeutics N/A -42.60%-37.76% SummaryAurora Cannabis beats Artiva Biotherapeutics on 7 of the 13 factors compared between the two stocks. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.97M$3.20B$5.87B$10.13BDividend YieldN/A2.30%5.68%4.60%P/E RatioN/A21.1774.5225.93Price / SalesN/A427.09516.21181.52Price / CashN/A46.6837.5660.44Price / Book0.339.6112.166.29Net Income-$65.37M-$53.29M$3.28B$270.77M7 Day Performance-29.36%0.12%0.78%3.84%1 Month Performance-4.49%5.60%4.87%4.85%1 Year Performance-74.40%10.47%60.72%26.00% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva Biotherapeutics3.1254 of 5 stars$2.55-4.1%$17.00+566.7%-76.3%$64.97MN/A0.0081Positive NewsACBAurora Cannabis0.5332 of 5 stars$5.42-3.6%N/A-13.8%$305.98M$246.72M-28.531,130LRMRLarimar Therapeutics2.6209 of 5 stars$3.62-7.4%$18.43+409.1%-45.7%$299.66MN/A-2.3230Positive NewsOCGNOcugen1.771 of 5 stars$1.02-2.9%$6.00+488.2%-10.8%$298.15M$4.05M-5.1080GLUEMonte Rosa Therapeutics2.6878 of 5 stars$4.80-0.6%$15.33+219.4%-19.3%$296.45M$75.62M13.3390Positive NewsDMACDiaMedica Therapeutics2.2293 of 5 stars$5.71-2.7%$12.33+116.0%+65.3%$295.14MN/A-8.2820Analyst UpgradeSCPHscPharmaceuticals4.5104 of 5 stars$5.50-0.2%$12.00+118.2%+6.0%$293.14M$36.33M-3.0430Positive NewsShort Interest ↓High Trading VolumeCTNMContineum Therapeutics2.6789 of 5 stars$10.45+4.0%$22.75+117.7%-31.6%$293.04M$50M-4.7531Short Interest ↑FDMT4D Molecular Therapeutics2.6752 of 5 stars$6.16-0.3%$30.40+393.5%-57.2%$287.69M$40K-1.75120News CoveragePositive NewsCAPRCapricor Therapeutics2.2106 of 5 stars$6.28+0.3%$22.56+259.2%+52.2%$287.10M$22.27M-3.83101Analyst ForecastFHTXFoghorn Therapeutics2.7484 of 5 stars$5.06+1.0%$10.67+110.8%-41.6%$286.04M$22.60M-4.25120Positive News Related Companies and Tools Related Companies ACB Alternatives LRMR Alternatives OCGN Alternatives GLUE Alternatives DMAC Alternatives SCPH Alternatives CTNM Alternatives FDMT Alternatives CAPR Alternatives FHTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTV) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
